Erectile dysfunction (ED) due to diabetes mellitus remains difficult to treat medically despite advances in pharmacotherapeutic approaches in the field.
This unmet need has resulted in a recent re-focus on the pathophysiology, in order to understand the cellular and molecular mechanisms leading to ED in diabetes. Diabetes-induced ED is often resistant to PDE5 inhibitor treatment, thus there is a need to discover targets that may lead to novel approaches for a successful treatment. The aim of this brief review is to update the reader in some of the latest development on that front, with a particular focus on the role of impaired neuronal blood flow and the formation of advanced glycation endproducts.
Written by:
Cellek S, Cameron NE, Cotter MA, Muneer A. Are you the author?
Department of Translational Medicine, Cranfield Health, Cranfield University, Bedfordshire, UK.
Reference: Int J Impot Res. 2013 Jan;25(1):1-6.
doi: 10.1038/ijir.2012.30
PubMed Abstract
PMID: 22914567
UroToday.com Investigative Urology Section
